- Home
- GLNG vs KRYS Comparison
GLNG vs KRYS Comparison
Compare GLNG & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLNG
- KRYS
- Stock Information
- Founded
- GLNG 1946
- KRYS 2015
- Country
- GLNG Bermuda
- KRYS United States
- Employees
- GLNG N/A
- KRYS N/A
- Industry
- GLNG Marine Transportation
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLNG Consumer Discretionary
- KRYS Health Care
- Exchange
- GLNG Nasdaq
- KRYS Nasdaq
- Market Cap
- GLNG 4.4B
- KRYS 3.6B
- IPO Year
- GLNG N/A
- KRYS 2017
- Fundamental
- Price
- GLNG $41.57
- KRYS $133.05
- Analyst Decision
- GLNG Strong Buy
- KRYS Strong Buy
- Analyst Count
- GLNG 4
- KRYS 8
- Target Price
- GLNG $50.13
- KRYS $211.13
- AVG Volume (30 Days)
- GLNG 1.4M
- KRYS 320.8K
- Earning Date
- GLNG 01-01-0001
- KRYS 08-04-2025
- Dividend Yield
- GLNG 2.41%
- KRYS N/A
- EPS Growth
- GLNG N/A
- KRYS 109.01
- EPS
- GLNG 0.03
- KRYS 4.16
- Revenue
- GLNG $257,915,000.00
- KRYS $333,448,000.00
- Revenue This Year
- GLNG $63.76
- KRYS $44.05
- Revenue Next Year
- GLNG N/A
- KRYS $46.15
- P/E Ratio
- GLNG $1,144.25
- KRYS $31.77
- Revenue Growth
- GLNG N/A
- KRYS 247.53
- 52 Week Low
- GLNG $28.31
- KRYS $122.80
- 52 Week High
- GLNG $44.36
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- GLNG 53.96
- KRYS 44.16
- Support Level
- GLNG $42.17
- KRYS $127.99
- Resistance Level
- GLNG $43.43
- KRYS $143.20
- Average True Range (ATR)
- GLNG 1.03
- KRYS 4.23
- MACD
- GLNG -0.04
- KRYS 1.01
- Stochastic Oscillator
- GLNG 32.43
- KRYS 44.48
About GLNG Golar Lng Ltd
Golar LNG Ltd is a midstream LNG company that operates in the transportation, regasification, liquefaction, and trading of LNG. The segment in which the group operates includes Shipping, FLNG (Floating Liquefaction Natural Gas vessels), and Corporate and other. It generates maximum revenue from the FLNG segment.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.